CTOs on the Move

NeuX Technologies

www.neuxtec.com

 
Tampa, Florida - NeuX Technologies is a health, wellness, fitness and human performance company developing proprietary products and solutions for chronic pain, musculoskeletal injuries, neuromuscular conditions/diseases, fitness and human performance.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.neuxtec.com
  • 3802 Spectrum Boulevard Suite 112D
    Tampa, FL USA 33612
  • Phone: 561.510.1882

Executives

Name Title Contact Details
Tim Brown
Chief Innovation Officer Profile

Similar Companies

Cricket Health

Cricket Health is a specialty kidney care provider of integrated nephrology and dialysis care for people with Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD). Cricket Health delivers world-class, technology-enabled multidisciplinary care both in-person and virtually to achieve the best outcomes possible for patients and the best value for partners, keeping patients healthy and out of the hospital, accelerating access to transplant, and increasing home dialysis adoption. We are committed to aligning the success of our company with those of our partners and the patients whom we serve.

Innovus Pharmateuticals

Innovus Pharma, headquartered in La Jolla, California, is an emerging pharmaceuticals company that delivers innovative and uniquely presented and packaged health solutions through its over-the-counter medicines and consumer and health products.

Cherokee Regional Clinic

Cherokee Regional Clinic is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Cherokee, IA. To find more information about Cherokee Regional Clinic, please visit www.cherokeermc.org

BANC mall

BANC mall is a High Point, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enterin Inc.

Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.